2 years ago

IMU Biosciences Secures £11.5M Series A to Advance AI-Powered Immune System Mapping

  • IMU Biosciences, a UK-based life science startup, has raised £11.5 million in Series A funding to further develop its AI-powered immune system mapping platform, CytAtlas

  • The platform combines immunophenotyping with AI to provide insights into immune system function for diagnostics and drug development

  • The funding round was led by Molten Ventures, with participation from LifeX Ventures.

      • ProblemHealthcare

      "mapping the human immune system to support diagnostics and drug development"

      Solution

      "building an 'atlas' for the immune system with an AI platform to identify and categorise cells, and provide clinicians and pharmaceutical developers with a clearer understanding of how the immune system can be used to combat disease"

      Covered on